More Opthea Limited news
Opthea LimitedASX: OPT

Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DME

Jan 6, 2020 at 9:59 PM EST · Issued by Opthea Limited

Filed with ASX · Jan 6, 2020 at 9:59 PM EST · 3 pages · English

On 6ix: 6ix.com/news/opthea-completes-recruitment-in-ph2a-trial-of-opt-302-in-dme

Opthea Limited on 6ix

Story so far

  • Opthea Completes Final Patient Visit in Phase 2b wAMD TrialMay 15, 2019
  • Opthea Ph2b Trial Advances With 2nd Positive Safety ReviewMar 7, 2019
  • Opthea confirms final patient enrolment in Ph2b wAMD trialNov 26, 2018

Earlier from Opthea

  • Opthea Equity Raising PresentationDec 1, 2019
  • Opthea Presentation for Ophthalmology Innovation SummitOct 10, 2019
  • Opthea Receives A$14.6m R&D Tax IncentiveSep 30, 2019
  • Opthea Presentation for EURETINA CongressSep 5, 2019
  • Opthea Ph2b of OPT-302 in wAMD to be Presented at EURETINASep 3, 2019

Later from Opthea

  • Opthea Completes Patient Dosing in Phase 2a DME TrialMar 29, 2020
  • Opthea Reports Positive Ph2a Trial Results of OPT-302 in DMEJun 9, 2020
  • S&P DJI Announces June 2020 Quarterly RebalanceJun 11, 2020
  • Corporate Presentation of Ph1b/2a DME Trial Data (ASRS)Jul 26, 2020
  • Opthea Completes Successful FDA and EMA Meetings for Phase 3Aug 20, 2020
All Opthea news releases↗

Follow Opthea into a list and get an email when it puts out news.

Follow Opthea
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer